Daily Bulletin

Men's Weekly

.

Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease.

DEP® cabazitaxel is a patented, detergent (polysorbate-80[1])-free, nanoparticle version of the conventional cancer drug,...

Read more: Australian biotech company Starpharma announces positive interim results from the prostate cancer...

Business News

Nutifood Partners With GippsNature for First Product Launch, Eyeing Global Growth

The Victorian Government delegation joined discussions during the visit The first GippsNature product signals a new chapter in Vietnam - Australia dairy ties. A New Cross-Border Dairy Initiative ...

Daily Bulletin - avatar Daily Bulletin

5 Tips for Maintaining Outdoor Furniture in Rentals

Think outdoor furniture is low-maintenance? Tell that to the sun, the rain, and the occasional possum that decides to test it out. If you’re managing a property, that outdoor setup isn’t just for sho...

Daily Bulletin - avatar Daily Bulletin

Finding the Best Removalists in Geelong, Victoria: What You Need to Know

Moving to a new home or office can be both exciting and stressful. The process involves a lot of planning, coordination, and effort to ensure that everything runs smoothly. One of the most important d...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business